BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32129200)

  • 1. Evaluation of the children with C3 glomerulopathy.
    Pinarbasi AS; Dursun I; Poyrazoglu MH; Akgun H; Bozpolat A; Dusunsel R
    Saudi J Kidney Dis Transpl; 2020; 31(1):79-89. PubMed ID: 32129200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
    Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
    Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C3G and Ig-MPGN-treatment standard.
    Noris M; Remuzzi G
    Nephrol Dial Transplant; 2024 Jan; 39(2):202-214. PubMed ID: 37604793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
    Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C
    Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
    Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
    Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
    Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
    Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
    Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL
    Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C3 nephritic factor associated with C3 glomerulopathy in children.
    Nicolas C; Vuiblet V; Baudouin V; Macher MA; Vrillon I; Biebuyck-Gouge N; Dehennault M; Gié S; Morin D; Nivet H; Nobili F; Ulinski T; Ranchin B; Marinozzi MC; Ngo S; Frémeaux-Bacchi V; Pietrement C
    Pediatr Nephrol; 2014 Jan; 29(1):85-94. PubMed ID: 24068526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
    Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
    Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 glomerulopathy: experience of a pediatric nephrology center.
    Yazılıtaş F; Kargın Çakıcı E; Kurt Şükür ED; Can G; Güngör T; Orhan D; Bülbül M
    Acta Clin Belg; 2021 Aug; 76(4):253-257. PubMed ID: 31914901
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
    Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
    Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab for treatment of rapidly progressive C3 glomerulopathy.
    Le Quintrec M; Lionet A; Kandel C; Bourdon F; Gnemmi V; Colombat M; Goujon JM; Frémeaux-Bacchi V; Fakhouri F
    Am J Kidney Dis; 2015 Mar; 65(3):484-9. PubMed ID: 25530108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy.
    Kerns E; Rozansky D; Troxell ML
    Pediatr Nephrol; 2013 Nov; 28(11):2227-31. PubMed ID: 23892798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series.
    Spartà G; Gaspert A; Neuhaus TJ; Weitz M; Mohebbi N; Odermatt U; Zipfel PF; Bergmann C; Laube GF
    Clin Kidney J; 2018 Aug; 11(4):479-490. PubMed ID: 30094012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of poor kidney outcome in children with C3 glomerulopathy.
    Pınarbaşı AS; Dursun I; Gokce I; Çomak E; Saygılı S; Bayram MT; Donmez O; Melek E; Tekcan D; Çiçek N; Yılmaz D; Tabel Y; Yıldırım ZY; Bahat E; Koyun M; Soylu A; Canpolat N; Aksu B; Çelakıl ME; Taşdemir M; Benzer M; Özçelik G; Bakkaloğlu SA; Düşünsel R
    Pediatr Nephrol; 2021 May; 36(5):1195-1205. PubMed ID: 33130981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological Significance and Renal Outcomes of Light Microscopic Patterns in Complement Component 3 Glomerulopathy.
    Wani AS; Zahir Z; Gupta A; Agrawal V
    Nephron; 2020; 144(5):228-235. PubMed ID: 32155638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
    Gupta N; Wakefield DN; Clapp WL; Garin EH
    Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.